To evaluate whether serum and urinary Golgi membrane protein 1 (GOLM1/GP73) could serve as biomarkers for chronic kidney disease (CKD).
Approach:
Study Design: Cross-sectional observational study involving 32 healthy individuals and 172 kidney disease patients across various CKD stages and acute kidney injury.
Measurements: Assessment of serum G73, urinary G73, urinary creatinine, and conventional renal markers using logistic regression, AUC, decision curve analysis, and ordinal regression.
Immunostaining: Kidney biopsies from 20 patients were immunostained for GP73.
Key Findings:
Serum G73 levels increased from healthy controls to CKD stages 4-5, with a decrease in CKD stage 5D (P < 0.001).
Urinary G73 and the urine G73-to-creatinine ratio declined progressively (P < 0.001).
Adding serum G73 to clinical models improved discrimination of advanced CKD (AUC increased from 0.81 to 0.85, DeLong P = 0.026).
Serum G73 showed modest ability to distinguish acute kidney injury from CKD (AUC 0.59–0.75).
Kidney GP73 immunostaining was weak and unchanged across stages.
Interpretation:
Serum G73 independently associates with CKD severity and adds diagnostic value to conventional models, particularly for advanced CKD.
Limitations:
The study was limited to a specific cohort and may not generalize to all populations.
Sensitivity analyses indicated no meaningful incremental value beyond eGFR or serum creatinine.
Conclusion:
Serum and urinary G73 are useful non-invasive biomarkers that could improve CKD staging.
Recent CDC advisories, testing updates, and immunization recommendations highlight developments in infectious diseases, immunization, and diagnostic testing relevant to physicians across multiple specialties.
